Business
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
PMA submission targeted for May 29, 2026 in alignment with FDAVantive commits to additional funding support ahead of PMA acceptance milestone TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2026 and provided a corporate update. The first quarter of 2026 marked continued pro
About this update from Spectral Medical Inc
[{"type":"image","alt":"Spectral Medical Inc.","displaySize":"","headline":null,"caption":"Spectral Medical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":216,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NbXa8xaNSIpHSiSlXWircA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09","width":216,"height":57},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/NbXa8xaNSIpHSiSlXWircA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09","width":216,"height":57}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"PMA submission targeted for May 29, 2026 in alignment with FDA","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Vantive commits to additional funding support ahead of PMA acceptance milestone ","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":141,"olType":false},{"type":"text","content":"TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2026 and provided a corporate update.","length":311,"tagName":"p"},{"type":"text","content":"The first quarter of 2026 marked continued progress across regulatory, clinical and commercial readiness initiatives as the Company advances toward submission of its U.S. Food and Drug Administration (“FDA”) Premarket Approval (“PMA”) application for Toraymyxin™ (“PMX”). During the quarter and subsequent to quarter-end, Spectral further strengthened the clinical and scientific foundation supporting PMX, highlighted by the publication of the Tigris trial in The Lancet Respiratory Medicine and presentation at the Society of Critical Care Medicine Annual Congress in Chicago","length":577,"tagName":"p"},{"type":"text","content":"The Company is targeting a PMA submission date of May 29, 2026, a timeline established in coordination with the FDA to support both submission readiness and efficient allocation of review resources. The timing reflects incorporation of complete 12-month mortali...